Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

被引:80
作者
Cremer, FW
Bila, J
Buck, I
Kartal, M
Hose, D
Ittrich, C
Benner, A
Raab, MS
Theil, AC
Moos, M
Goldschmidt, H
Bartram, CR
Jauch, A
机构
[1] Heidelberg Univ, Inst Human Genet, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany
[3] German Canc Res Ctr, Cent Unit Biostat, D-6900 Heidelberg, Germany
关键词
D O I
10.1002/gcc.20231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To delineate multiple myeloma (MM) subgroups and their clonal evolution, we analyzed 81 newly diagnosed patients by interphase fluorescence in situ hybridization using a comprehensive probe set for 10 chromosomes and two IGH rearrangements. A median of 5 probes per patient displayed aberrant signal numbers (range, 1-10). Additional copies most frequently found were for 15q22, 19q13, 9q34, 11q23, and 1q21. Losses commonly observed were of 13q 14.3, 17p 13, and 22q 11. Predominance of gain or loss was quantified by a copy number score (CS) for each patient. Two peaks (CS = +3 and CS = 0) were found by plotting patient copy number scores over CS values corresponding to hyperdiploid and nonhyperdiploid MM. Cluster analysis revealed four major branches: (i) gain of 9q, 15q, 19q, and/or 11q; (ii) deletion of 13q and t(4; 14); (iii) t(11; 14); and (iv) gain of 1q. Statistical modeling of an oncogenetic tree indicated that early independent events were gain of 15q/9q and/or 11q, t(11; 14); deletion of 13q followed by t(4; 14); and gain of 1q. Aberrations of 17p13, 22q11, 8p12, and 6q21 were found as subsequent events. MM with gain of I q was delineated as a subentity with significantly higher beta-2-microglobulin and lower hemoglobin levels, indicating a poor prognosis. From our results, we propose a model of MM for clonal evolution. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:194 / 203
页数:10
相关论文
共 54 条
[1]   Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
IMMUNOLOGICAL REVIEWS, 2003, 194 (01) :96-104
[2]  
Bergsagel PL, 2003, CLIN CANCER RES, V9, P533
[3]   Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization [J].
Cigudosa, JC ;
Rao, PH ;
Calasanz, MJ ;
Odero, MD ;
Michaeli, J ;
Jhanwar, SC ;
Chaganti, RSK .
BLOOD, 1998, 91 (08) :3007-3010
[4]   Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis [J].
Davies, FE ;
Dring, AM ;
Li, C ;
Rawstron, AC ;
Shammas, MA ;
O'Connor, SM ;
Fenton, JAL ;
Hideshima, T ;
Chauhan, D ;
Tai, IT ;
Robinson, E ;
Auclair, D ;
Rees, K ;
Gonzalez, D ;
Ashcroft, AJ ;
Dasgupta, R ;
Mitsiades, C ;
Mitsiades, N ;
Chen, LB ;
Wong, WH ;
Munshi, NC ;
Morgan, GJ ;
Anderson, KC .
BLOOD, 2003, 102 (13) :4504-4511
[5]   Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma [J].
Debes-Marun, CS ;
Dewald, GW ;
Bryant, S ;
Picken, E ;
Santana-Dávila, R ;
González-Paz, N ;
Winkler, JM ;
Kyle, RA ;
Gertz, MA ;
Witzig, TE ;
Dispenzieri, A ;
Lacy, MQ ;
Rajkumar, SV ;
Lust, JA ;
Greipp, PR ;
Fonseca, R .
LEUKEMIA, 2003, 17 (02) :427-436
[6]   Distance-based reconstruction of tree models for oncogenesis [J].
Desper, R ;
Jiang, F ;
Kallioniemi, OP ;
Moch, H ;
Papadimitriou, CH ;
Schäffer, AA .
JOURNAL OF COMPUTATIONAL BIOLOGY, 2000, 7 (06) :789-803
[7]   Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy [J].
Drach, J ;
Ackermann, J ;
Fritz, E ;
Krömer, E ;
Schuster, R ;
Gisslinger, H ;
DeSantis, M ;
Zojer, N ;
Fiegl, M ;
Roka, S ;
Schuster, J ;
Heinz, R ;
Ludwig, H ;
Huber, H .
BLOOD, 1998, 92 (03) :802-809
[8]   IMPROVED CYTOGENETIC ANALYSIS OF BONE-MARROW PLASMA-CELLS AFTER CYTOKINE STIMULATION IN MULTIPLE-MYELOMA - A REPORT ON 46 PATIENTS [J].
FACON, T ;
LAI, JL ;
NATAF, E ;
PREUDHOMME, C ;
ZANDECKI, M ;
HAMMAD, M ;
WATTEL, E ;
JOUET, JP ;
BAUTERS, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (04) :743-745
[9]   Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma [J].
Fassas, ABT ;
Spencer, T ;
Sawyer, J ;
Zangari, M ;
Lee, CK ;
Anaissie, E ;
Muwalla, F ;
Morris, C ;
Barlogie, B ;
Tricot, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) :1041-1047
[10]  
Fiserová A, 2002, NEOPLASMA, V49, P300